Barr Seeks FDA Approval Of Low-Dose Extended-Cycle Contraceptive Lo Seasonique
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA grants Lo Seasonique an Oct. 24 action date.
You may also be interested in...
Lybrel To Launch In July Following FDA Approval
Wyeth’s oral contraceptive is the first continuous-use product without a placebo phase or pill-free interval.
Changing Of The Seasonale: Barr’s Extended-Cycle Contraceptive Goes Generic
Company tries to hedge losses through “authorized” generic and follow-on Seasonique.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.